Pfizer (PFE), in collaboration with Bristol Myers Squibb, has introduced a direct-to-patient option for Eliquis®, potentially ...

TOKYO -- Roughly 2.5 million doses of oral COVID-19 medication bought by the Japanese government during the pandemic expired ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...

Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.